Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Big Pharma Biotechnology and Pharmaceuticals Bristol Myers Squibb business Cancer Clinical trial conference Deal Eli Lilly European Commission European Union Facebook FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News

Upcoming Webcast: Data Driven Laboratory Asset Management Programs
Unlock unknown capital and drive efficiency while improving quality and scientist experience
Wednesday, June 17, 2009 at 10 AM EST
With increasing pressure in the pharmaceutical and biotech industry to reduce the costs of developing new drugs, more companies are looking at consolidating suppliers and partnering with global providers to enable them gain economies of scale, unify processes and increase productivity across all sites and functions.
More companies are starting to focus on their laboratory assets, how these are maintained, how validation is carried out, how downtime affects their operations and scientists’ productivity, how those assets are being utilized and whether they have over/under capacity.
Our lifecycle asset management programs go well beyond asset maintenance and provide you with a future proof solution that will improve scientist productivity, support capital investment strategies, help drive efficiency through multiple functions without compromising quality or scientist experience.
Register Free at www.pharmexec.com/datadriven
Sponsor:
GE Healthcare